Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects

Next Previous
Search
Trial Profile

Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tinlarebant (Primary)
  • Indications Stargardt disease
  • Focus Registrational; Therapeutic Use
  • Acronyms DRAGON
  • Sponsors Belite Bio

Most Recent Events

  • 29 Apr 2025 According to a Belite Bio media release, the data from this study will be presented as poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4-8, 2025, in Salt Lake City, Utah.
  • 27 Feb 2025 According to a Belite Bio media release, this trial is expected to complete by Q4 2025 (including a three-month follow-up period).
  • 27 Feb 2025 According to a Belite Bio media release, the company has completed a planned interim analyses which was performed when all subjects completed the one-year assessment. An independent Data Safety Monitoring Board (DSMB) for this study has recommended to continue without any modifications, maintaining the sample size at 104 subjects based on the treatment effect observed at the Interim Analysis. In addition, the DSMB recommended to submit the data for further regulatory review for drug approval.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top